140 related articles for article (PubMed ID: 11531830)
41. Predictive model for immunotherapy of alopecia areata with diphencyprone.
Wiseman MC; Shapiro J; MacDonald N; Lui H
Arch Dermatol; 2001 Aug; 137(8):1063-8. PubMed ID: 11493099
[TBL] [Abstract][Full Text] [Related]
42. Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone: evaluation of 68 cases.
Pericin M; Trüeb RM
Dermatology; 1998; 196(4):418-21. PubMed ID: 9669118
[TBL] [Abstract][Full Text] [Related]
43. Diphenylcyclopropenone treatment of alopecia areata induces apoptosis of perifollicular lymphocytes.
Herbst V; Zöller M; Kissling S; Wenzel E; Stutz N; Freyschmidt-Paul P
Eur J Dermatol; 2006; 16(5):537-42. PubMed ID: 17101475
[TBL] [Abstract][Full Text] [Related]
44. Alopecia areata in children: treatment with diphencyprone.
Schuttelaar ML; Hamstra JJ; Plinck EP; Peereboom-Wynia JD; Vuzevski VD; Mulder PG; Oranje AP
Br J Dermatol; 1996 Oct; 135(4):581-5. PubMed ID: 8915150
[TBL] [Abstract][Full Text] [Related]
45. Chronic delayed-type hypersensitivity reaction as a means to treat alopecia areata.
Zöller M; Freyschmidt-Paul P; Vitacolonna M; McElwee KJ; Hummel S; Hoffmann R
Clin Exp Immunol; 2004 Mar; 135(3):398-408. PubMed ID: 15008971
[TBL] [Abstract][Full Text] [Related]
46. Expression of vascular endothelial growth factor, apoptosis inhibitors (survivin and p16) and CCL27 in alopecia areata before and after diphencyprone treatment: an immunohistochemical study.
Simonetti O; Lucarini G; Bernardini ML; Simoncini C; Biagini G; Offidani A
Br J Dermatol; 2004 May; 150(5):940-8. PubMed ID: 15149507
[TBL] [Abstract][Full Text] [Related]
47. Treatment of alopecia areata with diphenylcyclopropenone.
van der Steen PH; van Baar HM; Perret CM; Happle R
J Am Acad Dermatol; 1991 Feb; 24(2 Pt 1):253-7. PubMed ID: 2007671
[TBL] [Abstract][Full Text] [Related]
48. Diphenylcyclopropenone immunotherapy in ophiasis.
Singh G; Okade R; Naik C; Dayanand CD
Indian J Dermatol Venereol Leprol; 2007; 73(6):432-3. PubMed ID: 18032873
[No Abstract] [Full Text] [Related]
49. Fexofenadine hydrochloride enhances the efficacy of contact immunotherapy for extensive alopecia areata: Retrospective analysis of 121 cases.
Inui S; Nakajima T; Toda N; Itami S
J Dermatol; 2009 Jun; 36(6):323-7. PubMed ID: 19500180
[TBL] [Abstract][Full Text] [Related]
50. Topical immunotherapy for alopecia areata: re-evaluation of 139 cases after an additional follow-up period of 19 months.
van der Steen PH; Boezeman JB; Happle R
Dermatology; 1992; 184(3):198-201. PubMed ID: 1392112
[TBL] [Abstract][Full Text] [Related]
51. Impaired responses of peripheral blood mononuclear cells to staphylococcal superantigen in patients with severe atopic dermatitis: a role of T cell apoptosis.
Yoshino T; Asada H; Sano S; Nakamura T; Itami S; Tamura M; Yoshikawa K
J Invest Dermatol; 2000 Feb; 114(2):281-8. PubMed ID: 10651987
[TBL] [Abstract][Full Text] [Related]
52. Topical immunotherapy with diphencyprone in the treatment of extensive and/or long-lasting alopecia areata.
Firooz A; Bouzari N; Mojtahed F; Pazoki-Toroudi H; Nassiri-Kashani M; Davoudi M; Dowlati Y
J Eur Acad Dermatol Venereol; 2005 May; 19(3):393-4. PubMed ID: 15857483
[No Abstract] [Full Text] [Related]
53. Application of Topical Immunotherapy in the Treatment of Alopecia Areata: A Review and Update.
Mahasaksiri T; Kositkuljorn C; Anuntrangsee T; Suchonwanit P
Drug Des Devel Ther; 2021; 15():1285-1298. PubMed ID: 33790540
[TBL] [Abstract][Full Text] [Related]
54. Alopecia areata. Pathogenesis and topical immunotherapy.
Perret CM; Steijlen PM; Happle R
Int J Dermatol; 1990 Mar; 29(2):83-8. PubMed ID: 2182554
[No Abstract] [Full Text] [Related]
55. Alopecia areata in children: response to treatment with diphencyprone.
Hull SM; Pepall L; Cunliffe WJ
Br J Dermatol; 1991 Aug; 125(2):164-8. PubMed ID: 1911299
[TBL] [Abstract][Full Text] [Related]
56. Alopecia areata is characterized by expansion of circulating Th2/Tc2/Th22, within the skin-homing and systemic T-cell populations.
Czarnowicki T; He HY; Wen HC; Hashim PW; Nia JK; Malik K; Estrada Y; Kimmel GW; Taliercio M; Krueger JG; Guttman-Yassky E
Allergy; 2018 Mar; 73(3):713-723. PubMed ID: 29083474
[TBL] [Abstract][Full Text] [Related]
57. Modified immunotherapy for alopecia areata.
Yoshimasu T; Furukawa F
Autoimmun Rev; 2016 Jul; 15(7):664-7. PubMed ID: 26932732
[TBL] [Abstract][Full Text] [Related]
58. Alopecia Areata: a Comprehensive Review of Pathogenesis and Management.
Trüeb RM; Dias MFRG
Clin Rev Allergy Immunol; 2018 Feb; 54(1):68-87. PubMed ID: 28717940
[TBL] [Abstract][Full Text] [Related]
59. IL-17 inhibition: is it the long-awaited savior for alopecia areata?
Ramot Y; Marzani B; Pinto D; Sorbellini E; Rinaldi F
Arch Dermatol Res; 2018 Jul; 310(5):383-390. PubMed ID: 29497840
[TBL] [Abstract][Full Text] [Related]
60. Growth factor mRNA levels in alopecia areata before and after treatment with the contact allergen diphenylcyclopropenone.
Hoffmann R; Wenzel E; Huth A; van der Steen P; Schäufele M; König A; Happle R
Acta Derm Venereol; 1996 Jan; 76(1):17-20. PubMed ID: 8721483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
